New York, NY -- (SBWIRE) -- 12/03/2013 -- PennyStockChronicle covers the breadth of the markets, from NASDAQ, NYSE, AMEX, ETF, Penny Stocks, Emerging Markets, activities at the Fed and more. PennyStockChronicle brings you the most vibrant coverage of following stocks: Star Scientific, Inc (NASDAQ:STSI), Buka Ventures Inc (OTCBB:NNRX), Dyax Corp (NASDAQ:DYAX), J.C. Penney Company, Inc (NYSE:JCP)
Star Scientific, Inc (NASDAQ:STSI) showed a volume of 1.39million shares by the end of last trade whereas the average volume of the stock remained 1.22 million shares. The stock opened the session at $1.39 but then moved to $1.29. At that price, the stock showed a negative performance of -0.77%. Star Scientific, Inc. (Star Scientific) is engaged in the manufacturing and production of dietary supplements. The Company’s operating subsidiaries manufacture, distribute and sell consumer products and dietary supplements. Its segment includes dietary supplements. Through its Rock Creek Pharmaceuticals, Inc. (Rock Creek) subsidiary, the Company is engaged in the manufacture, sale, marketing and development of non-nicotine nutraceutical, dietary supplements: Anatabloc, for anti-inflammatory support;
Will STSI Get Buyers Even After The Recent Rally? Find Out Here
Buka Ventures Inc (OTCBB:NNRX) opened the session at $0.92 and closed the session at $0.965. The stock showed a positive performance of 4.90% in previous trading session. Traded with volume of 3.91 million shares in the prior session and the average volume of the stock remained 1.17 million shares.
For How Long NNRX will fight for Profitability? Read This Trend Analysis report
Dyax Corp (NASDAQ:DYAX) opened the session at $8.59 and closed the session at $8.81. The stock showed a positive performance of 3.65% in previous trading session. Traded with volume of 2.53 million shares in the prior session and the average volume of the stock remained 1.77 million shares. The beta of the stock remained 1.77. Dyax Corp. (Dyax), is a biopharmaceutical company with two business elements: Angioedema Franchise and Phage Display Licensing and Funded Research Program. It is focused on identifying and developing treatments for patients who experience plasma kallikrein (bradykinin) mediated angioedema. The principal focus of Dyax is to identify, develop and commercialize treatments for conditions identified as plasma kallikrein (bradykinin) mediated angioedema,
Why Should Investors Buy DYAX After The Recent Gain? Just Go Here and Find Out
J.C. Penney Company, Inc (NYSE:JCP) the stock decreased -1.77% and finished the session at $10.01. Traded with volume of 39.41 million shares in the prior session and the average volume of the stock remained 40.92 million shares. The beta of the stock remained 1.78. J. C. Penney Company, Inc. (jcpenney) is a holding company. The Company is a retailer, operating 1,102 department stores in 49 states and Puerto Rico as of January 28, 2012. Its business consists of selling merchandise and services to consumers through its department stores and through its Internet Website at jcp.com. It sells family apparel and footwear, accessories, fine and fashion jewelry, beauty products through Sephora inside jcpenney and home furnishings.
Will JCP Get Buyers Even After The Recent Rally? Find Out Here
Penny Stock Chronicle is comprised of a team of vetted penny stock traders who’ve been trading since 2008 & have developed the skills needed to trade for consistent profits.
PLEASE NOTE WELL: The employees of PennyStockChronicle.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockChronicle.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockChronicle.com is not offering securities for sale. Neither PennyStockChronicle.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockChronicle.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockChronicle.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer at: http://pennystockchronicle.com/disclaimer
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)